Structure-based design of cyclooxygenase-2 selectivity into ketoprofen

Area of Science:

• Medicinal Chemistry
• Computational Chemistry
• Pharmacology

Background:

• Non-selective NSAIDs like indomethacin can cause side effects.
• Selective cyclooxygenase-2 (COX-2) inhibitors offer improved safety profiles.
• Previous work established a pharmacophore and 3D models for designing COX-2 selective inhibitors from indomethacin.

Purpose of the Study:

• To design novel COX-2 selective analogues of the NSAID ketoprofen.
• To leverage computational modeling and medicinal chemistry for structure-based drug design.
• To identify potent and selective COX-2 inhibitors based on the ketoprofen scaffold.

Main Methods:

• Utilized a previously developed pharmacophore model.
• Employed comparative molecular modeling of ketoprofen docked into COX active sites.
• Applied the GRID program to analyze enzyme active site differences.
• Incorporated traditional medicinal chemistry techniques for analogue design.

Main Results:

• Successfully designed and synthesized a series of ketoprofen analogues.
• Identified compound 17 (LM-1669) as a potent and selective COX-2 inhibitor.
• Demonstrated the utility of the combined computational and medicinal chemistry approach.

Conclusions:

• The study successfully generated selective COX-2 inhibitors based on the ketoprofen structure.
• Computational modeling and pharmacophore-based design are effective strategies for developing isoenzyme-selective drugs.
• The identified compounds, particularly LM-1669, represent promising leads for further development.